Shiven Patel
Overview
Explore the profile of Shiven Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Neal J, Santoro A, Gonzalez-Cao M, Lim F, Fang B, Gentzler R, et al.
JTO Clin Res Rep
. 2024 Sep;
5(10):100666.
PMID: 39318387
Introduction: We evaluated efficacy and safety of cabozantinib plus atezolizumab or cabozantinib alone in advanced NSCLC previously treated with an immune checkpoint inhibitor (ICI). Methods: COSMIC-021 (NCT03170960) is a phase...
2.
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma
Mansfield A, Vivien Yin J, Bradbury P, Kwiatkowski D, Patel S, Bazhenova L, et al.
Lung Cancer
. 2024 Aug;
195:107928.
PMID: 39197359
Purpose: The mesothelin-targeting antibody-drug conjugate anetumab ravtansine was evaluated in combination with the programmed cell death-1 (PD-1) inhibitor pembrolizumab based on the common expression of mesothelin and reports of activity...
3.
Patadia R, Casale T, Fowler J, Patel S, Cardet J
Expert Opin Biol Ther
. 2024 Apr;
24(4):251-261.
PMID: 38619468
Introduction: Asthma encompasses a spectrum of phenotypes often categorized into two groups- type 2 high (T2 high) and type 2 low (T2 low). T2 high includes atopic and eosinophilic presentations...
4.
Sama S, Kerrigan K, Sinnott J, Puri S, Akerley W, Haaland B, et al.
Cancer Treat Res Commun
. 2023 Feb;
35:100686.
PMID: 36736060
Introduction: Limited-stage small-cell lung cancer (LS-SCLC) is potentially curable with concurrent chemoradiation (CRT). Cisplatin is the preferred platinum for the chemotherapy backbone in national guidelines. Unfortunately, many LS-SCLC patients are...
5.
Griffiths E, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, et al.
J Natl Compr Canc Netw
. 2022 May;
20(5):436-442.
PMID: 35545171
The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia...
6.
Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, et al.
JTO Clin Res Rep
. 2022 Mar;
3(3):100280.
PMID: 35243411
Introduction: Malignant pleural mesothelioma (MPM) is an aggressive malignancy that affects older adults with frequent comorbidities, making real-world treatment decisions challenging. This study compares the overall survival (OS) of patients...
7.
Kerrigan K, Wang X, Haaland B, Adamson B, Patel S, Puri S, et al.
Clin Lung Cancer
. 2021 Mar;
22(4):260-267.e2.
PMID: 33678584
Background: Non-small cell lung cancer (NSCLC) in never-smokers (NS) is vastly different from those with a smoking history in terms of etiology, driver mutations, and immunotherapy responsiveness. This study compares...
8.
Patel S, Shah T, Sabara P, Bhatia D, Panchal K, Italiya J, et al.
3 Biotech
. 2020 Sep;
10(9):414.
PMID: 32983825
Here, we designed a custom panel targeting whole β-casein gene SNPs of zebu and taurine cattle breeds to identify variants and applicability in dairy cattle genotyping. We sequenced two libraries...
9.
Baron K, Moser J, Patel S, Grossmann K, Colonna S, Hyngstrom J
J Oncol Pharm Pract
. 2020 May;
27(3):555-559.
PMID: 32423325
Introduction: Anti-PD-1 antibodies are commonly used as frontline therapy for patients with metastatic melanoma. Although these medications can cause long term responses, a significant number of patients will not respond...
10.
Moser J, Wei G, Colonna S, Grossmann K, Patel S, Hyngstrom J
Acta Oncol
. 2020 Jan;
59(4):434-437.
PMID: 31920132
Pembrolizumab (P) and nivolumab (N) are commonly used therapies for advanced melanoma. However, their effectiveness has never been directly compared, leaving little guidance for clinicians to select the best therapy....